Related Experiment Video
Updated: Jun 25, 2026
07:53
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
[Multiple myeloma with variant type translocation, t(8;22)(q24;q11.2)]
Akiko Sugiyama1, Hiroko Nakabayashi, Manabu Kondo
1Division of Hematology, Department of Medicine, Yamaguchi Prefectural Medical Center.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|February 20, 2009
Summary
A 68-year-old patient with multiple myeloma achieved complete remission. Treatment with dexamethasone and thalidomide effectively reduced cancer cells and chromosomal abnormalities.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma is a hematologic malignancy characterized by the proliferation of plasma cells in the bone marrow.
- Anemia and bone pain are common presenting symptoms.
Observation:
- A 68-year-old female presented with anemia and bone pain, indicative of potential hematologic disorders.
- Bone marrow examination revealed immature plasma cells with intermediate differentiation (CD38 gating flow cytometry) and a monoclonal increase in IgA, lambda-type.
Findings:
- Cytogenetic analysis identified complex chromosomal abnormalities, including a variant translocation t(8;22)(q24;q11.2) with the breakpoint downstream of c-MYC.
- The patient was diagnosed with multiple myeloma featuring this variant translocation.
Implications:
- This case highlights a rare variant translocation in multiple myeloma, emphasizing the importance of comprehensive cytogenetic analysis.
- Effective treatment with continuous infusion dexamethasone and oral thalidomide led to complete remission, reducing IgA levels, plasma cell burden, and chromosomal abnormalities.
